Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Unknown 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Uveal Melanoma 1Solid Tumor 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Glioma 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 47Specimen Handling 29Magnetic Resonance Spectroscopy 25Biopsy 25Radiosurgery 17Gemcitabine 17Nivolumab 15Paclitaxel 14Cyclophosphamide 13Cisplatin 13Carboplatin 13Bevacizumab 12Drug Therapy 11Taxes 10Radiotherapy 10Oxaliplatin 10Leucovorin 10Irinotecan 10Fluorouracil 10Capecitabine 10trastuzumab deruxtecan 8fludarabine 8Pemetrexed 8Doxorubicin 8Cetuximab 8cemiplimab 7abemaciclib 7Trastuzumab 7Fulvestrant 7Docetaxel 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Metastasis × Valproic Acid × Clear all
NCT05821556 2026-04-14

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

National Cancer Institute, Naples

Phase 2 Recruiting
240 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡